Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Biostem Technologies Inc. is a biomedical company specializing in the development of regenerative medicine solutions. The company is primarily engaged in creating and distributing innovative biologic products that promote the repair and regeneration of tissues. A significant focus of Biostem Technologies is on allogeneic biologic products derived from human tissue, which serve clinical applications in areas such as wound care, orthopedics, and ophthalmology. Through its research and development efforts, the company aims to deliver advanced healing solutions that enhance the quality of medical care and improve patient outcomes. Biostem Technologies plays a vital role in the growing field of regenerative medicine, which has profound implications for various sectors, including healthcare and biotechnology. Catering to markets in need of cutting-edge therapeutic options, Biostem is positioned as a significant player in the pursuit of innovative medical solutions, contributing to advancements in personalized and precision medicine.
$3.80
+$0.19 (+5.26%)
EOD Aug 12, 2026
10.34% operating margin is respectable but not wide. ROIC at 124.82%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 1708.9% YoY with margins expanding 57.0pp.
Even for strong businesses, today's 3x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
2.6x earnings, 3.7x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$309M
▲ +1708.9% YoY
Net Income (TTM)
$32M
▲ +475.9% YoY
Op. Margin
10.40%
▲ +57.0pp YoY
ROIC
124.82%
▲ +250.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
$24M
▲ +748.4% YoY
Op. Cash Flow (FY)
$24M
▲ +799.5% YoY
Net Debt
-$18M
Net Cash Position
Cash & Equiv.
$23M
3Y CAGR: +311.2%
Continue Research
At a P/E of 2.6 and a price-to-free-cash-flow of 3.7, Biostem Technologies (BSEM) trades below a two-stage DCF intrinsic value of about $26.57 per share, so at $3.80 the stock looks undervalued (599.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Biostem Technologies scores 84/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $26.57 per share for BSEM, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $19.93. At today's $3.80, that puts the stock about 599.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Biostem Technologies scores 84 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 10.4% operating margin and a 124.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BSEM currently trades below its estimated intrinsic value and scores 84/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.